Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 2. Abbasi BA, Iqbal J, Ahmad R et al. Potential phytochemicals in the prevention and treatment of esophagus cancer: a green therapeutic approach. Pharmacol. Rep. 71(4), 644–652 (2019).
  Medline CASGoogle Scholar
• 3. Eslick GD. Epidemiology of esophageal cancer. Gastroenterol. Clin. North Am. 38(1), 17–25 (2009).
  MedlineGoogle Scholar
• 4. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 381(9864), 400–412 (2013).
  MedlineGoogle Scholar
• 5. Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154(2), 360–373 (2017).
  MedlineGoogle Scholar
• 6. Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, Group EGW. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6), vi51–56 (2013). • Current guidelines on the management of esophageal cancer.
  MedlineGoogle Scholar
• 7. Yoshino T, Arnold D, Taniguchi H et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; a JSMO – ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 29(1), 44–70 (2018). • Current guidelines on the management of esophageal cancer.
  Medline CASGoogle Scholar
• 8. Kitagawa Y, Uno T, Oyama T et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus 16(1), 25–43 (2019). • Current guidelines on the management of esophageal cancer.
  MedlineGoogle Scholar
• 9. Jimenez P, Pathak A, Phan AT. The role of taxanes in the management of gastroesphageal cancer. J. Gastrointest. Oncol. 2(4), 240–249 (2011).
  Medline CASGoogle Scholar
• 10. Ken K, Makoto T, Shuichi H et al. A Phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemoth. Pharm. 67(6), 1265–1272 (2011).
  MedlineGoogle Scholar
• 11. Muro K, Hamaguchi T, Ohtsu A et al. A Phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann. Oncol. 15(6), 955–959 (2004).
  Medline CASGoogle Scholar
• 12. Hossein B, Luis PA, Leora H et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl. J. Med. 373(17), 123–135 (2015).
  MedlineGoogle Scholar
• 13. Antonia SJ, López-Martin JA, Bendell J et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, Phase I/II trial. Lancet Oncol. 17(7), 883–895 (2016).
  Medline CASGoogle Scholar
• 14. Wolchok JD, Harriet K, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. New Engl. J. Med. 369(2), 122 (2013).
  Medline CASGoogle Scholar
• 15. Mazza C, Escudier B, Albiges L. Nivolumab in renal cell carcinoma: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 9(3), 171 (2017).
  Medline CASGoogle Scholar
• 16. Jiang Y, Lo AWI, Wong A et al. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget 8(18), 30175–30189 (2017).
  MedlineGoogle Scholar
• 17. Zhang W, Pang Q, Yu SF, Yuan Z, Wang P, Xiao Z. PD-L1 is prognostic factor of human esophageal squamous cell carcinoma and its association with EGFR in radiation therapy. Int. J. Radiat. Oncol. 96(2), S29 (2016).
  Google Scholar
• 18. Kudo T, Hamamoto Y, Kato K et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, Phase II trial. Lancet Oncol. 18(5), 631–639 (2017).
  Medline CASGoogle Scholar
• 19. Kato K, Cho BC, Takahashi M et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, Phase III trial. Lancet Oncol. 20(11), 1506–1517 (2019). •• This is the full publication of the ATTRACTION3 study.
  Medline CASGoogle Scholar
• 20. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost–effectiveness analysis. Health Econ. 9(3), 235–251 (2000). •• This is the guideline on how to establish a cost–effectiveness analysis.
  Medline CASGoogle Scholar
• 21. Wu B, Ye M, Chen H, Shen JF. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin. Ther. 34(2), 468–479 (2012).
  MedlineGoogle Scholar
• 22. Wu B, Li T, Cai J, Xu Y, Zhao G. Cost–effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer 14(1), 984 (2014).
  MedlineGoogle Scholar
• 23. Tan C, Peng L, Zeng X et al. Cost–utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese national comprehensive cancer network (NCCN) clinical practice guidelines in oncology: gastric cancer. Pharmacoeconomics 32(3), 235–243 (2014).
  MedlineGoogle Scholar
• 24. Bai Y, Xu Y, Wu B. Cost–effectiveness and budget impact analysis of apatinib for advanced metastatic gastric cancer from the perspective of health insurance system. Gastroent. Res. Pract. 2017(1), 1–7 (2017).
  Google Scholar
• 25. Wu B, Zhang Q, Sun J. Cost–effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J. Immunother. Cancer 6(1), 124 (2018).
  MedlineGoogle Scholar
• 26. Lu S, Ye M, Ding L, Tan F, Fu J, Wu B. Cost–effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget 8(6), 9996–10006 (2017).
  MedlineGoogle Scholar
• 27. Saito S, Muneoka Y, Ishikawa T, Akazawa K. Cost–effectiveness of paclitaxel + ramucirumab combination therapy for advanced gastric cancer progressing after first-line chemotherapy in Japan. Clin. Ther. 39(12), 2380–2388 (2017).
  Medline CASGoogle Scholar
• 28. Dieleman JL, Campbell M, Chapin A et al. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet 389(10083), 2005–2030 (2017). • Describes the future and potential spending on healthcare worldwide.
  MedlineGoogle Scholar
• 29. Dieleman JL, Templin T, Sadat N et al. National spending on health by source for 184 countries between 2013 and 2040. Lancet 387(10037), 2521–2535 (2016). • Describes the future and potential spending on healthcare worldwide.
  MedlineGoogle Scholar
• 30. Sassan O, Jin GC, Jacqueline NC et al. Cost–effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors. J. Clin. Oncol. 36(Suppl. 4), 56–56 (2018).
  Google Scholar